Updated Amplatzer Amulet Instructions: Pulmonary Artery Injury Risk

Three bands turn anatomy into a safety decision

The FDA recall record dated October 15, 2026, describes updated instructions for the Amplatzer Amulet Left Atrial Appendage Occluder intended to address pulmonary artery injury risk. The central change is a distance-based framework: 1.5 mm or less, more than 1.5 mm through 3.0 mm, and greater than 3.0 mm.

These are not interchangeable findings. A measurement at or below 1.5 mm identifies the closest relationship and the greatest concern for interaction between the implanted device and the neighboring pulmonary artery. That anatomy should weigh strongly against proceeding with Amulet implantation and should prompt consideration of another closure strategy, where appropriate.

The middle band—more than 1.5 mm through 3.0 mm—is not a declaration of safety. It identifies limited separation and calls for heightened scrutiny of anatomy, device selection and the anticipated final position. The potential benefit of left atrial appendage closure must be weighed against the device-specific injury risk before implantation.

A distance greater than 3.0 mm places the anatomy in the lowest of the three specified risk bands. It does not certify that implantation is risk-free or replace the rest of the instructions for use. Operators still need to assess appendage dimensions, device sizing, position, stability and surrounding structures.

The boundaries matter. A value of exactly 1.5 mm belongs in the first category, while 3.0 mm remains in the middle category. Measurement uncertainty also matters when a result lies close to either cutoff. Clinicians should apply the imaging method and anatomic landmarks specified in the current instructions rather than rounding a borderline measurement into a more favorable band.

What the regulatory evidence can establish

This is a regulatory safety correction, not a randomized comparison of the three distance groups. The cited FDA recall entry supplies the revised thresholds and identifies the injury concern, but it does not function as a clinical study report with a prespecified population, comparator, effect estimate, confidence interval or follow-up period. The bands should therefore be understood as risk-management criteria in the labeling, not as validated estimates of an individual patient’s absolute probability of injury.

The original FDA approval materials provide broader evidence on the device’s safety and effectiveness for left atrial appendage occlusion. The pivotal Amulet IDE trial randomized 1,878 patients with nonvalvular atrial fibrillation to Amulet or the first-generation Watchman device. At 12 months, the composite safety outcome occurred in 14.5% and 14.7%, respectively, a difference of −0.14 percentage points with a 95% confidence interval from −3.42 to 3.13; Amulet met the trial’s noninferiority criterion.

At 18 months, ischemic stroke or systemic embolism occurred in 2.8% of each group, with a between-group difference of −0.06 percentage points and a 95% confidence interval from −1.55 to 1.43. Procedure-related complications were more frequent with Amulet, at 4.5% versus 2.5%, mainly because of pericardial effusion and device embolization.

Those trial findings establish the device’s overall premarket evidence context, but they do not validate the newly specified pulmonary artery distance bands. The trial preceded this labeling update and was not designed or powered to compare outcomes at 1.5 mm and 3.0 mm boundaries.

How the thresholds should change implantation planning

The distance assessment should occur early enough to influence device choice, not after a commitment to Amulet has already been made. The operator should use the imaging modality, views and landmarks required by the current instructions for use. Multiplanar review is important because a single projection can obscure the shortest relationship between the appendage, the expected device position and the pulmonary artery.

For anatomy in the first band, the safety signal should not be managed simply by selecting a smaller device or accepting a different position unless the updated instructions explicitly support that approach. Device size and position can affect contact, but they do not create additional anatomic space. An alternative left atrial appendage closure device or another stroke-prevention strategy may offer a more appropriate risk profile.

The intermediate band requires the most judgment. Teams should document the measurement, its reproducibility, the proposed device size and why the expected benefit justifies the residual risk. If image quality is inadequate or measurements straddle a threshold, obtaining better imaging or choosing the more conservative category is more defensible than treating the cutoff as precise beyond the data.

A value above 3.0 mm answers only one safety question. It does not establish suitability for left atrial appendage closure, determine antithrombotic management or rule out other procedural complications. All remaining indications, contraindications, sizing requirements and follow-up provisions in the current label still apply.

The recall is an instructions update rather than evidence that every implanted Amulet should be removed. Decisions for people with an existing device should be based on symptoms, imaging findings, time since implantation and the regulator’s current follow-up recommendations. Prophylactic extraction carries its own hazards and is not supported merely by learning that a preimplant distance was small.

Important uncertainties remain

The public recall record does not provide event rates for each distance category, the number of patients from whom the thresholds were derived, or confidence intervals around the cutoffs. It also does not show whether risk rises smoothly as distance narrows or changes abruptly at 1.5 mm and 3.0 mm.

Measurement variability may limit generalizability across imaging protocols, readers and centers. The available regulatory evidence also cannot determine whether technique, device size or specific appendage morphology modifies risk within a band. Postmarket analyses with standardized imaging and adjudicated outcomes are needed to quantify absolute risk and test the reproducibility of these thresholds.

Questions clinicians ask

Does a measurement above 3.0 mm make Amulet implantation safe?

No. It indicates lower concern for this particular pulmonary artery interaction under the revised framework. The patient must still satisfy the device’s indication and all other anatomic, sizing and procedural requirements, and clinicians must consider the broader risks of left atrial appendage closure.

What should happen when the measurement is exactly 1.5 or 3.0 mm?

Exactly 1.5 mm falls in the highest-concern category; exactly 3.0 mm remains in the intermediate category. Because small differences in acquisition or interpretation can change classification, borderline measurements warrant careful review using the method and landmarks specified in the current instructions.

Do the thresholds apply to other left atrial appendage closure devices?

Not automatically. The update concerns the Amplatzer Amulet and its relationship to adjacent anatomy. Different devices have different shapes, anchoring mechanisms and labeling, so these numerical bands should not be transferred to another system without device-specific evidence or instructions.

Should an asymptomatic patient with an existing Amulet undergo removal?

The recall record does not, by itself, support routine prophylactic removal. Management should follow current FDA and manufacturer recommendations and account for symptoms, imaging and procedural risk; explantation or surgical removal may expose the patient to substantial harm and requires individualized specialist review.

References

1. Medical Device Recall: Amplatzer Amulet Left Atrial Appendage Occluder — US Food and Drug Administration, 2026 2. Summary of Safety and Effectiveness Data: Amplatzer Amulet Left Atrial Appendage Occluder — US Food and Drug Administration, 2021 3. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis: A Randomized, Controlled Trial — Circulation, 2021